September 26, 2020. Johnson & Johnson laga experimental COVID-19 vaccine para single dose deya beche novel coronavirus oper te tangor immune response toh mid stage clinical trial samay hoishe, koikena Friday din interim results janai thishe. Vaccine laga nam toh Ad26.COV2.S, ase koishe, tuita(2) alag-alag doses deya samay rokaboli parishe, result para thikaishe. Ekta shot aro Moderna Inc aro Pfizer Inc laga tuita(2) dose test korikena vaccine toh thiboli echa ase koishe.
Hoilebi, pura manuh kaun khan virus nemite besi risk ase, tai khan logot J&J vaccine para jawan manuh ke protect kora neshina hobo nai clear nai koishe. Trial toh 1,000 healthy jawan manuh khan logot loishe aro U.S. government para be motob thishe. July moina te J&J vaccine toh monkey logot single dose deya beche tangor protection kora nemite manuh logo soruh korishe. Etu khobor bhal nemite Wednesday din te J&J para final 60,000 manuh ke trial loboli koishe. Company para koishe ke, Phase 3 trial laga result toh etu saal kotom phali nohoile aha saal soruh samay olaboli bhapana ase. Medical website medRxiv te result ola toh aro peer-reviewed kora nai koishe.(https://bit.ly/2G3Ni1X) J&J’s unit Janssen Pharmaceuticals researchers para koishe ke, 98% participants laga data interim analysis kora toh neutralizing antibodies ase aro cells ke pathogens para pajaikena rakishe, vaccine loikena 29 din beche ase koishe. Hoilebi, immune response kora results toh komti manuh tai khan 15 jun thakishe. 65 umer oper manuh logot dhuk paa aro muscle beka toh 36% para komti thakishe, jawan manuh khan 64% thakishe, etu nemite result hesab te immune response toh umer besi manuh khan logot toh tangor nathakibo koishe. Researchers para aro koishe ke, study kotom kora bechete safety aro effectiveness laga details toh bhal para saboli koishe. Etai, serious kam sabo nemite studies toh tangor chaka te koriboli lage, koikena Harvard T.H. Chan School of Public Health laga professor Dr. Barry Bloom para Reuters ke koishe, hoilebi tai toh J&J trial te shamil nai.
Add Comment